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IS THERE ANYTHING NEW? 
Heliiohartev pylori has been for many years a forgotten 
bacterium, since the first reports on this spiral organism 
date from the nineteenth century [l]. As early as 1906, 
an association between a spiral organism and gastric 
carcinoma was suggested ['I. Doenges reported in 1938 
that, on autopsy, no fewer than 40% of human stomachs 
were found to be invaded by spiral organisms [3]. In 
1940, the therapeutic effect of bismuth in patients with 
peptic ulcer disease in the presence of spiral bacteria in 
the stomach was reported [4]. Interest in the bacterium 
then decreased. In 1982, two Australian researchers, 
Marshall and Warren, rediscovered the microbe [ S ] ,  and 
called it first Carnpylobaitcv pylori, and later Heliiobuctcv 
pylori. Today, the complete genome (1590 genes) of 
H .  pylori has been unmasked [6] and published on the 
internet (http://www.tigr.org), probably paving the 
way for sequencing the genomes of other organisms, 
including that of humans within a few years [7]. 
WHY IS HELICOBACTER PYLORI SO IMPORTANT? 
There is unequivocal evidence that N. pylori can be 
considered as a healthcare issue because of the mortality 
associated with the infection, due to the risk of ulcer 
bleeding and gastric cancer. Infection with H .  pylori 
results in the development of gastritis in all infected 
humans, including children and adolescents IS]. World- 
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wide, peptic ulcer disease is a major cause of morbidity 
and distal gastric adenocarcinoma, which is the second 
biggest cancer killer worldwide [9]. However, the 
majority of infected individuals will remain free of 
symptoms throughout their lifetime; only a small 
minority will present with peptic ulcer disease (lifetime 
risk 15%). and an even smaller proportion will develop 
gastric neoplasms, including niucosa-associated lym- 
phoid tissue lymphoma and adenocarcinorna (lifetime 
risk 0.1%) [lo]. Overall, H .  pylori can be discovered in 
97% of children with duodenal ulcers and in 35'5, of 
children with gastric ulcers [ l l ] .  H .  pylovi infection is 
contracted primarily in childhood, and infection from 
childhood appears to enhance the risk for carcino- 
genesis [ 121. 
ABOUT THE BACTERIUM: VIRULENCE 
The micro-aerophilic, Gram-negative, urease-producing 
H .  pylori fulfills each of Koch's postulates [XI. In its 
normal living form it is a spiral-shaped bacterium, but 
the coccoid form can also cause lesions. The bacterium 
colonizes the stomach of humans and induces severe 
mucosal inflammation and a local and systemic immune 
response. The bacterium is capable of changing its 
niembrane potential at external pH levels from 3.0 to 
7.0 in order to maintain a neutral internal pH [13]. All 
H. pylovi strains are not created equal [ l - t ]  and not all 
strains are associated with clinical symptoms. 
Some virulence factors such as urease and flagell'a 
are present in all strains and are necessary for patho- 
genesis and colonization. Flagella, and thus motility, are 
needed for persistent gastric colonization [ 151. The 
gene Flh.4 is needed for flagellar expression [ 161. 
Enzymes produced by H .  pylori have mostly nietabolic, 
antioxidant and toxic properties [17]; most of these are 
produced by all isolates tested. Urease is required to 
establish infection, and is located intra- and extra- 
cellularly [ 151. Urease is a nickel-containing metallo- 
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enzyme, composed of two structural subunits, UreA 
and UreB 1181. Urease is primarily a cytoplasmic 
enzyme [19], and hydrolyzes urea to bicarbonate and 
ammonia, resulting in a net increase in the ambient pH. 
Ammonia is a nutrient for the bacteria, and causes 
lesions of the gastric epithelium by many different 
mechanisms 1301. Surface urease helps to protect against 
acid exposure, but it is as yet unclear why it is found 
on bacteria deep underneath gastric mucus, where the 
pH is thought to be neutral. Because there is no  
obvious urease export machinery, it has been suggested 
that some bacteria undergo autolysis, following which 
released proteins, including active urease, are absorbed 
onto the surface of remaining intact bacteria [19,31]. 
Urease might function as an adhesin, although this 
suggestion has also been contradicted ”31. Urease 
stimulates the release of a variety of inflammatory 
cytokines, including IL-p, IL-6, TNF-a, and chemo- 
kines such as IL-8 [33]. Although the exact mechanism 
by which urease functions in the pathogenesis of gastric 
disease remains unclear, it is likely that urease is an 
important virulence factor. 
H .  pylori can produce different kinds of phospho- 
lipases, weakening the hydrophobicity of the gastric 
mucus and mucosa. Phospholipase can also generate 
ulcerogenic substances 1341. Many other enzymes, such 
as mucinase, neuraminidase, fucosidase and alcohol 
dehydrogenase, have been reported 1301. 
The vacuolating cytotoxin A (vacA) gene is present 
in all strains, but is only expressed in 50% of H. pylori 
isolates 1351. The vacuolating activity of t!ucA is 
increased by exposure to acidic pH values 1261. The 
vacuoles are formed by merging of late endosomes, and 
the mechanism causing this has been determined 1371. 
The vucA gene exhibits different allelic combinations. 
Strains with the gene s l / m l  have the highest levels of 
cytotoxic activity, colonize the stomach more densely 
and are correlated with peptic ulcer, atrophic gastritis 
and gastric cancer; s2/rn2 strains have no toxic activity 
Other virulence factors, such as ‘cytotoxic- 
associated gene A’ (cagA)-encoded proteins, are only 
found in a proportion of the strains. This might explain 
why not all strains are associated with clinical symptoms, 
although both cagA and the s l  z ~ u u l  allele are unreliable 
as single markers in determining the risk of developing 
peptic ulcer disease 1191. The cagA protein product is a 
cryptic 138-kDa immunodominant antigen produced 
by H. pylovi. cagA is a marker for a larger cluster of genes 
(40 different genes 1201) carried on a pathogenicity 
island that exhibits variability between strains 1301. 
CagAf strains produce increased amounts of IL-8 
1301. Gastric atrophy, duodenal ulceration and gastric 
carcinoma are more common in patients infected with 
[30,2S]. 
CagA+ than with CagA- strains [31]. CagA- strains are 
very rare in some Far East countries such as China and 
Korea and frequent in others such as Hong Kong. 
However, allelic variations in CagA are found in 
different parts of the world. In Western countries, 
CagA+ strains are associated with gastric atrophy and 
peptic ulcer disease [32]. Other putative virulence 
determinants are being discovered, such as the neutro- 
Phil-activating protein (napA) gene, a gene ‘induced by 
contact with epithelium’ (iceA I), etc. 1201. However, 
according to recent data, it is suggested that there is no 
correlation between the degree of inflammation and 
the presence of the cag pathogenicity island, cytotoxin 
production, and ijacA alleles associated with cytotoxin 
expression in children [33]. 
Auto-immunity and host mimicry by expression 
of blood group antigens may be a relevant pheno- 
menon. Adhesion of H. pylori is non-specific, although 
preferential to epithelial cells, and is enhanced at low 
pH, inducing epithelial cell reorganization and causing 
deep invagination of the apical membrane, explaining 
resistance to topical antibiotic treatment 1341. One host 
receptor for adhesion appears to be a blood group 0 
antigen, possibly explaining why ulcers are more 
common in people with this blood group 1351. The 
H. pylori lipopolysaccharide (LPS) or endotoxin is 
unusually biologically inert compared to that from 
other bacteria. However, the mechanisms by which 
H. pylovi LPS stimulates cells appear to be similar to 
those of other types of bacterial LPS [36]. H. pylori LPS 
often contains Lewis x and Lewis y blood group 
antigens that are identical to those occurring in the 
gastric mucosa 1371. H. pylovi presents bacterial epitopes 
to the host which are similar to the structure on host 
gastric epithelium; therefore, the host reacts with an 
auto-antibody response recognizing gastric mucosa, 
inducing atrophic gastritis 1381. Patients with a large 
parietal cell mass and high acid secretion will have 
predominantly antral gastritis, predisposing to duodenal 
ulcer 1391. People with a small parietal mass and 
low acid output (or people receiving proton pump 
inhibitors (PPIs)) will be more prone to develop 
atrophic gastritis and gastric malignancy 1391. The 
variability in occurrence of gastric cancer in different 
parts of the world can only partly be explained by the 
prevalence of H. pylori. Apoptosis of gastric epithelial 
cells is increased in H. pylori infection, stimulating crypt 
cell proliferation, and increasing the risk for muta- 
genesis 1401. Atrophic gastritis enhances the develop- 
ment of intestinal metaplasia, and is related to the 
intestinal type of gastric carcinoma but not to diffuse 
gastric carcinoma 1411. Intestinal metaplasia is related to 
atrophic gastritis, which is, in turn, related to H. pylori 
infection. 
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SYMPTOMS 
H. pylori gastritis, in the absence of duodenal ulcer, does 
not appear to be associated with specific syniptoms 
[l  1,42-44]. After eradication of H. pylori infection, 
symptoms are improved only in those children with 
duodenal disease [43]. Children with W. pylori gastritis 
cannot be distinguished from non-infected children on 
the basis of initial syniptoms [.la]. 
Many studies, however, have failed to demonstrate 
a difference in H. pylori infection rate between children 
with or without recurrent abdominal pain [11,45]. It is 
unclear whether children with recurrent abdominal 
pain with H. pylori represent a different entity to those 
without H. pylori. H. pylori-positive children might 
more often have pain related to meals than H. pylori- 
negative children. Ulcer-like symptoms may be more 
closely associated with the infection than other symp- 
tom complexes 1461. 
In adults, a significantly lower H. pylori prevalence 
is reported in patients with gastro-esophageal reflux 
disease 1-17], The role of H. pylori in duodenogastric 
reflux is unclear. Decreased mean acid output in 
subjects with H .  pylori gastritis might explain the 
inverse relationship between reflux and H. pylori. 
Heartburn and epigastric pain might be more frequent 
in H. pylori-infected patients. Pooled data from 18 
studies suggest that the prevalence of H .  pylori is greater 
in patients with dyspepsia than in controls 1.161. It is 
unclear whether H .  pylori changes gastric emptying 
rate or not, although most data suggest that gastric 
emptying is normal [48-501. 
Similarly to other chronic inflammatory conditions, 
infection with H. pylori has been linked to reduced 
growth [5 1-54], although socio-economic factors 
confuse the issue. TNF-a is inversely correlated with 
growth, and is increased in W. pylori [55]. However, 
studies have also failed to find differences in hemo- 
globin, leukocytes, thrombocytes, weight and height 
1451. Differences in growth seem to be limited to 
developing countries 1541. After controlling for socio- 
economic status, there is no difference between the 
height of adults with and without H. pylori. H. pylori 
seropositivity is related to a late menarche [56,57]. 
Socio-economic status and malnutrition do not explain 
late menarche, since elevated body mass index is also 
independently associated with H. pylori in the same 
population 1571. Incidentally, anemia, hemoptysis and 
vertigo have been reported [58]. 
The association of H. pylori with extra-digestive 
dseases, such as functional vascular diseases and skin 
and endocrine autoimmune diseases, has been 
described [59-62]. An interesting relationship between 
seropositivity to H. pylori, serum glucose and non- 
insulin-dependent diabetes mellitus is worthy of further 
attention. Recent studies suggest that the association 
between H .  pylori and coronary heart disease is rather 
weak 1591. Primary Raynaud’s phenomenon, observed 
in young women, which is defined by intermittent 
vasospasm of the arterioles of the distal limbs that 
occurs niostly following exposure to cold or emotional 
stimuli, may be related to H. pylori in some cases 
[60]. H .  pylori may in addition cause headache [60]. 
Vasoactive substances, such as cytokines (interleukins, 
IFN-y, TNF-a),  prostaglandins, leukotrienes, o q -  
radicals, C-reactive protein and fibrinogen, are released 
in chronic infection [60]. Henoch-Schonlein purpura 
and Sjogren’s syndrome have been correlated with 
the presence of the bacterium. Many patients with 
auto-immune thyroid diseases are infected with type 
I cytotoxic C a d +  strains 1611. Rosacea and recurrent 
urticaria may also be associated with H. pylori infection 
[62]. Alopecia areata is associated with atrophic gastritis 
and pernicious anemia, and thus with H .  pylori [60]. 
Until now, H .  pylori has not yet been reported to cause 
hepatitis in humans although a mouse Helirobacter 
species has been reported to cause hepatitis in germ- 
free mice, and H .  pylori has been identified in the 
gallbladders of humans [63,64]. 
HELlCOBACTER PYfORl IN INFANTS AND CHILDREN 
Independent risk factors for H. pylori infection in 
infants and children include living in developing 
countries, lower socio-economic Ftatus, living in 
overcrowded circumstances and sharing a bed with a 
parent. Human lactoferrin can support H. pylori growth 
in vitro, and H .  pylori binding lactoferrin has now been 
identified. Infants born to seropositive mothers passively 
acquire maternal H. pylori IgG 1651. Transplacentally 
transferred maternal anti-Hi. pylori IgG lasts until about 
the third month of life in most infants and disappears 
from nearly all by 6 months 1651. IgA in the mother’s 
milk protects the infant from H. pylori infection [66). 
However, whether breast-feeding is associated with a 
low or high prevalence of H. pylori infection in infants 
is still unclear [65,67,68] (protective effect of the 
mother’s milk versus intimate contact between the 
infant and an H .  pylori-positive mother). At the age 
of 14 months, 7.5% of infants in a population with 
a seroprevalence in young adults of 63% had acquired 
H. pylori, an event demonstrated by a rise in IgM, 
quickly disappearing and preceding IgG [65,69, 
701. In an industrialized country (Belgium), less than 
1% of infants are seropositive at  the age of 1 year 
[71] (seropositivity in young adults is about 30%) 
171,721. 
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DIAGNOSTIC AND SCREENING TOOLS 
Many invasive and non-invasive methods have been 
used to diagnose H. pylori infection in humans [73]. 
Culture of the organism is the best standard method for 
the diagnosis of any bacterial infection. H. pylori can 
be cultured from gastric biopsies. Culture of H. pylori 
requires a micro-aerobic atmosphere of 5% oxygen 
with 5-10% COz. When H. pylori is cultivated on 
biopsy, sensitivity to antibiotics should be tested [74]. 
Whether or not coccoidal forms also grow in blood 
agar is controversial [75,76]. 
Histologic examination of Giemsa- or Warthin- 
Starry stained gastric biopsy specimens is widely used 
for diagnosis. The Sydney criteria for the classification 
ofgastritis have been revised [77]. Gastric biopsy urease 
tests make use of a change in color ofphenol red which 
is present in the medium because of a pH increase 
related to the digestion of urea by the urease. Four 
rapid urease tests are available commercially: CLO-test 
(Delta West Ltd, Bentley, Australia), Hpfast (GI Supply, 
Philadelphia, PA, USA), Pyloritek (Serin Research 
Corporation, Elkhart, USA), and Jatrox (Rohm 
Pharma GmbH, Weiterstadt, Germany), although many 
hospitals prepare their own urease tests. These com- 
mercial tests have high specificity and sensitivity and 
provide comparable results [78]. Antral and corpus 
biopsies provide comparable results, and in combina- 
tion they increase the sensitivity by 4.3% 1791. Although 
these biopsy urease tests have a high degree of sensi- 
tivity in adults, false-negative results are common in 
children, possibly because of a smaller bacterial load 
Molecular methods for biopsy material or other 
biological samples and current P C R  methods for 
molecular fingerprinting of H. pylori have been 
developed [81]. P C R  techniques can quantitate the 
bacterial load in gastric samples [82]. Several molecular 
methods have been applied to the typing of H .  pylori 
isolates, demonstrating their genomic diversity. Unfor- 
tunately, all these tests necessitate endoscopy. 
Magnetic beads coated with anti-H. pylori rabbit 
antibodies permit detection of less than 10 million 
organisms per gram of feces 1831. P C R  detection of 
H. pylori in feces is hindered by the presence of 
inhibitors of Taq polymerase, complex polysaccharides 
which can be eliminated by filtration on Qiagen and 
dilution. Nevertheless, the technique is not routinely 
available. 
The ability to detect antibodies in saliva rather than 
in serum would improve antibody tests by avoiding 
the need for blood collection. Sensitivity [84%) and 
specificity (70%) are too low, but comparable with 
those of rapid whole blood diagnostic tests [84,85]. The 
I801. 
discovery of the potential importance of the cugA 
pathogenicity island has stimulated interest in the 
specific detection of the cagA protein. 
Serologic testing for IgG antibodies against H. pylori 
requires validation of the assay in children, since anti- 
body levels differ between children and adults, probably 
because of the duration of infection and the differences 
in bacterial load [69,86]. In addition, commercially 
available serologic tests demonstrate lower accuracy 
compared with testing in a research setting [87], with 
sometimes up to 33% false-positive and 25% false- 
negative results [88,89]. Testing should not rely on 
office tests [74]. After eradication, there is a slow 
decline in antibody titer. Many patients remain sero- 
positive 1 year after eradication [90]. At acquisition 
of the infection, there is a temporary rise in IgM 
[65,69,70,91]. IgA is also reported to be a useful 
serologic screening tool [92]. Immunoblot has become 
the reference method for confirming doubtful results 
Carbon-13 and carbon-14 breath tests are based on 
the fact that urease from H .  pylovi will hydrolyze the 
ingested labeled urea into ammonia and labeled 
bicarbonate, which is exhaled as labeled carbon dioxide 
[18]. Whether a test meal should be given, whether the 
labeled urea should simply be given after a period of 
fasting, or whether addition of citric acid would be 
beneficial, is not clear [94-961. A standardized and 
simplified 13C breath test was recently described in 
children [97]. The high sensitivity and specificity of the 
breath test in the detection of H. pylori infection in 
children have been unequivocally demonstrated [98]. 
The best cut-off value is obtained after 30 min [95]. 
False-positive results can occur because of the presence 
of other urease-containing gastric bacteria or because 
of extragastric bacterial urea metabolism (rare). False- 
negative results are mainly due to fast gastric emptying 
or previously administered urease-inhibiting drugs, 
such as antibiotics or bismuth-containing salts. There is 
a close correlation between the urea breath test and the 
intragastric bacterial load [79,99], which is, in turn, 
related to the severity of the gastritis. Unfortunately, 
13C breath tests are still expensive in many parts of 
the world. A less expensive method for the analysis of 
13C-labeled carbon dioxide is non-dispensive infrared 
spectrometry, which has comparable sensitivity and 
specificity [loo]. But infrared spectrometry necessitates 
larger volumes of expired air, making the technique less 
suitable for (small) children. Alternatively, measurement 
of 14C-labeled carbon dioxide with a scintillation 
counter is relatively inexpensive [loll .  Although the 
dose required for one test is not greater than the natural 
background radiation, the use of 14C is considered 
unethical in pregnant women, adolescents and children 
P31. 
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because of its extremely long half-life, which means 
that it may be incorporated into the bicarbonate pool. 
EPIDEMIOLOGY 
The prevalence of H. pylori infection in many 
populations and/or subgroups is currently well 
documented. Like many other childhood bacterial 
infections, H. pylori is most frequently acquired in the 
pre-school age group, with the associated effects of 
family size, clustering in families, low socio-economic 
status and education and variable risks associated with 
gender [102]. Recent socio-cultural changes may result 
in changes in infection rates in children [103], which is 
an important argument for the cohort effect. In 
general, it is thought that spontaneous eradication of 
H. pylori infection is extremely rare [104,105]. Some 
authors suggest that up to 10% of spontaneous 
eradication occurs in a period of 6 month during 
childhood [106]. These discrepancies may, however, be 
related to the methodology (serology versus urea breath 
test). 
In the developed world, acquisition by adults is 
approximately 3% per decade [107], and this will result 
in a dramatic decrease in H .  pylori infection in that 
part of the world in the coming decades. In The 
Netherlands, about 40% of the 60-69-year-old popu- 
lation is seropositive [107]; since the prevalence in 
adolescents is below 10% [108], it can be speculated 
that the seropositivity of this cohort will probably not 
be higher than 25% when they reach the age of 70 years. 
Reinfection probably does not occur frequently 
and is, in many cases, considered to be recrudescence 
after treatment failure. Reinfection rates vary strongly 
with the effectiveness of the treatment protocol [109]. 
In Chile, reinfection occurred in 4.2% after 1 year, with 
a treatment protocol that was 82% effective [110]. The 
percentage of reinfection does not appear to be much 
greater in developing countries than in developed 
regions. As a consequence, there is little reason to treat 
an entire family to prevent reinfection, although spread 
from one adult to another has been suggested [ l l l ] .  
It seems more likely that reinfection occurs from an 
external source. O f  course, a more detailed specification 
of the H.  pylori strain will contribute to determin- 
ing whether reinfection rather than relapse occurs. 
Repetitive extragenetic palindromic P C R  can group 
isolates into clusters that appear to have different clinical 
expressions [81]. Oligonucleotide probes containing 
short repetitive sequence motifs can differentiate 
between different isolates of H .  pylori [112]. 
The major mode(s) of transmission of H. pylori are 
still unknown: oral-oral, gastro-oral and fecal-oral 
have been proposed [113,114]. House-flies could serve 
as vectors for H. pylori [115]. Pets have also been 
suggested to be vectors. There is considerable evidence 
of transmission of oral bacteria between spouses and 
between family members [ l l l ] .  Vomiting and gastro- 
esophageal reflux might also constitute a mode of 
oral-oral contamination [116]. The mode of spread 
remains an active area of study, with water as a source 
of contamination still of potential interest. The coccoid 
form can cause cellular changes similar to those caused 
by the spiral form [117], and may serve as the infectious 
form in environmental sources such as water [118]. 
Studies on external water sources in Peru revealed P C R  
products of H.  pylori in the municipal water, increasing 
by 12 times the risk for infection [119]. The examples 
of studies in Peru and Chile suggest a role for water as 
a vehicle, but it does not seem to be the main route of 
acquisition, since many studies in Korea [103], Taiwan 
and Turkey do not support this hypothesis. 
HOST RESPONSE TO H. PYLORl 
Another factor contributing to the heterogeneity of 
H. pylori-associated symptoms is the variability in 
host response to the infection. Duodenal bicarbonate 
secretion is decreased in ulcer patients, and returns to 
normal after eradication of H. pylori [ 120,12 11. Acute 
H. pylori infection has been associated with hypo- 
chlorhydria, possibly by stimulating the production of 
a histamine-3 receptor agonist, which inhibits gastric 
acid output. In contradiction to this finding is the 
observation that the same histamine-3 receptor agonist 
can stimulate parietal cells to produce acid via the 
histamine-2 receptor [122]. Identification of Lewis 
carbohydrate structures on H. pylori LPS may provide 
an explanation for the development of autoantibodies 
reacting with gastric mucosa (‘molecular mimicry’) 
[123]. 
TREATMENT 
The regimens that have been studied to date have used 
bismuth preparations, H2-receptor antagonists, ranitidme 
bismuth citrate, proton pump inhibitors (PPIs) and 
various antibiotics. The goal of any treatment should 
be to achieve an eradication rate of over 80% on a 
rigorous intention-to-treat basis [74]. Most European 
H. pylori study groups now recommend (in adults) a 
triple regimen: a twice-daily dose of PPI in com- 
bination with two antibiotics from the following three 
groups: clarithromycin; amoxycillin; nitroimidazoles 
(metronidazole or tinidazole) for 1 week [74,124,125]. 
There are as yet no specific recommendations for 
children [126]. It has been hypothesized that com- 
bination therapy is more effective because of the 
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synergistic mechanisms between different drugs. The 
requirement is for a simple, well-tolerated, cost- 
effective regimen, with which it is easy to comply. 
In a recent Irish study in children, the therapeutic 
approach consisted of colloidal bismuth citrate 
(480 mg/1.73 m2 body surface, 4 weeks) in com- 
bination with amoxycillin (750 mg per day, 2 weeks) or 
metronidazole (20 mg/kg/day, 2 weeks) [95]. In most 
European countries, eradication treatment in children 
usually consists of a PPI in combination with amoxy- 
cillin and either clarithromycin or nitroimidazole, 
based on the sensitivity of the prevailing strains. 
Although antibiograms are needed, there seem to be 
major discrepancies between in vitro testing and in vivo 
efficacy. Resistance to amoxycillin has not yet been 
reported. Resistance to macrolides is rising with 
increasing use of the drugs, and for both macrolides and 
nitroimidazoles there is a huge regional variation in 
resistance patterns. 
Bismuth triple therapy continues to achieve high 
eradication rates worldwide (78-89%). Side effects 
leading to diminished patient compliance and the 
marked decline of eradication efficacy in cases of 
metronidazole resistance are considered to be the major 
drawbacks of this therapy. PPI dual therapy is better 
tolerated with fewer side effects than is bismuth triple 
therapy. The mean eradication rates vary from 55% to 
75%, and the extremes lie between 24% and 93%. PPI 
triple therapies have been shown to be very effective 
against H. pylori (eradication rate of 80-90%). Quad- 
ruple therapy leads to a mean eradication rate of 
96%. Thus, based on efficacy, PPI triple or bismuth 
triple therapy are recommended as first-line treatment 
11271. The cost of PPI versus bismuth should be 
considered. 
Eradication therapy is not recommended for all 
H. pylori-infected adults and children [126]. However, 
the complex relationship between H. pylori and gastro- 
intestinal cancer might stimulate the physician to 
prescribe eradication treatment, even in the absence of 
scientific evidence, especially in countries with a strong 
impact of legislation on health care, as is the case in the 
USA. In children, not one randomized prospective 
placebo-controlled study has been conducted. There 
is no evidence to support treatment in children with 
symptomatic H. pylori gastritis alone [95]. Well-designed 
clinical trials showing a therapeutic gain of H. pylori 
treatment over placebo are still missing, with the 
exception of duodenal ulcer patients. The codbenefit 
ratio of avoiding endoscopy in dyspeptic patients is only 
worth considering if the cost of endoscopy is greater 
than US$500 11281, as is the case in the USA; the cost 
of upper gastrointestinal tract endoscopy in Belgium is 
about US$lOO. 
Nevertheless, recommendations in Europe and 
the USA differ. The European consensus states that 
scientific evidence for the improvement of functional 
dyspepsia is equivocal, but the overall evaluation, taking 
into account the expected benefit for the gastritis status, 
makes it worthwhile to consider eradication therapy in 
such a patient. In Europe, it is accepted (although 
not unanimously) that young patients, aged below 45 
years, without alarm symptoms (anemia, weight loss, 
dysphagia, palpable mass, malabsorption, etc.) and who 
test positive for H. pylori for the first time (with 
validated serology or breath test), can be treated with 
eradication therapy without further investigation (thus, 
without endoscopy) 174,1241. However, in the USA, 
the present consensus states that there is no scientific 
evidence to recommend treatment for H. pylori in 
the absence of established peptic ulcer disease [120]. 
As a consequence, according to the North American 
consensus, non-invasive testing cannot replace endo- 
scopy in the initial diagnosis of H .  pylori-related 
gastrointestinal diseases (also not in children) 11291. 
Eradication of H. pylori in patients who do not benefit 
from it may unnecessarily increase the risk of resistance 
of H. pylori to antibiotics. 
H. pylori and non-steroidal anti-inflammatory drugs 
(NSAIDs) are both ulcerogens; however, NSAIDs are 
not frequently prescribed in children, and, moreover, 
there seems to be no cooperative effect between them. 
As a consequence, eradication of H. pylori prior to 
NSAID administration is not recommended in the 
USA. In Europe, eradication of H. pylori before 
NSAIDs is considered to be ‘advisable’. 
Elimination of H. pylori increases the risk of 
developing gastroesophageal reflux and reflux esophagitis 
[121,130]. H. pylori eradication results in a marked 
decrease in the pH-increasing effect of omeprazole 
and ranitidine 11311. Nevertheless, long-term acid 
suppressive therapy with PPIs (and, to a lesser extent, 
with H2-antagonists) for reflux disease in H. pylori- 
positive patients enhances the development of atrophic 
gastritis, if H. pylori has not been eradicated beforehand 
[132,133]. 
Eradication of H. pylori can be demonstrated by 
normalization of histology and negative culture of 
gastric biopsies, or with the use of urea breath tests [74]. 
With respect to serology, a 50% fall in antibody titers 
is indicative of successful elimination. However, this 
usually requires up to 6 months to occur 11341. When 
follow-up tests for eradication of H. pylori are necessary, 
they should not be performed earlier than 4 weeks after 
cessation of treatment 1741. The bacterial load could 
influence the success rate of eradication treatment [135]. 
Knowledge of the H. pylori genome provides major 
new insights into many aspects. Conversion of pyruvate 
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to acetyl-CoA requires an unusual enzyme, only 
previously found in free-living bacteria from extreme 
environments [136], and the genome sequence shows 
that acetyl-CoA is likely to be a crucial intermediary 
in several biosynthetic pathways. Therefore, blocking of 
the enzyme should allow effective and selective drug 
activity against H .  pylori. The same is true for many 
other enzymes. 
VACCINATION 
Study of the H .  pylovi outer membrane is important, 
both for understanding pathogenicity and for develop- 
ment of vaccines, since the outer membrane is involved 
in adherence to the host epithelium and stimulation of 
the host immune response. Vaccines should be able to 
confer preventive and curative immunity on humans. 
Oral immunization with a recombinant urease given in 
the absence of a mucosal adjuvant has been unsuccessful 
in H .  yylovi-infected volunteers [137] (urease is a cyto- 
plasmic enzyme). However, recently, the recornbinant 
H .  pylori urease was given with an Esclierichiu coli heat- 
lable toxin, provoking diarrhea in the majority of the 
volunteers (a side effect which disappeared when the 
dose was reduced), but also causing an increase in 
urease-specific IgA-producing cells and a decrease in 
the density of gastric colonization by H .  pylori [138]. 
IgA antibodies are expected to play a prominent 
role in protectior., since H .  pylori is a non-invasive 
pathogen at the luniinal surface of the gastric niucosa. 
This hypothesis has been supported by the observation 
that inilk IgA protects infants against H. pylori infection 
[66]. IgA and inimunoglobulin GI (IgGl) depend on 
T-helper type 2 (Th2) cells. According to different 
recent experiments, immunization is associated with an 
elevation of IgG, levels, indicative of a Th2 cellular 
immune response, which might be a significant mech- 
anism 1139-1411. The field of vaccination is still very 
controversial, and is being extensively studied. 
CONCLUSION 
H .  pylori infection is, worldwide, one of the most 
frequent infectious diseases. There are huge discrep- 
ancies in prevalence and incidence between the 
Western industrialized countries and the rest of the 
world (Africa, Asia, South America). Infection occurs 
mainly in children. Because of the cohort effect, which 
is related to the socioceconomic status and/or hygienic 
circumstances, the annual infection rate in the Western 
world is dramatically decreasing. If this observation is 
confirmed, it can be speculated that a decrease in the 
incidence of peptic ulcer disease and gastric cancer may 
occur in the industrialized world during the next 
decades. (However, duodenal ulcer and gastric cancer 
are only related to some-more virulent-strains.) 
Many children remain asymptomatic, and a clear 
relationship between H. pylori and symptoms has only 
been demonstrated €or ulcer-related symptoms. In 
addition, peptic ulcers are rare in childhood. Treatment 
of H. pylovi is indicated in duodenal ulcer disease. 
The relationship between chronic abdominal pain (and 
functional dyspepsia) and H .  pylovi is unclear. 
Screening tests, including serology or the urea 
breath test, are of interest for epidemiologic studies. 
The urea breath test evaluates the actual colonization; 
serum antibodies might persist after eradication, which 
is only rarely spontaneous. According to the European 
consensus, eradication therapy can be considered in a 
child with functional dyspepsia and positive screening 
test. According to the North American consensus, 
treatment is only recommended in the presence of 
ulcer, necessitating endoscopy. 
H. pylovi strains are not all equal, since important 
virulence factors are not detectable in all strains. The 
continuous decline of H .  pylori prevalence as a result of 
changes in living conditions and active treatment is not 
unanimously considered to be beneficial [14]. Unfortu- 
nately, screening tests rely on virulence factors which 
are detectable in all strains: the presence of urease, or 
the immune response of the host by measuring IgG 
antibodies. Vaccines will not become available in the 
near future. 
Nevertheless, in all countries, improvement of 
socio-economic status and hygienic circumstances will 
result in a dramatic decrease of H .  pylori infection. 
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